Zydus Lifesciences Limited recently said that it has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Lidocaine and Prilocaine Cream USP, 2.5%/2.5%. This topical anesthetic is used for local pain relief on normal, intact skin and genital mucous membranes, making it useful for minor surgeries and as a pretreatment for infiltration anesthesia. The cream will be manufactured at Zydus' Changodar facility in Ahmedabad.

Lidocaine and Prilocaine Cream has seen annual sales of USD 22.05 million in the U.S. market, according to IQVIA data (MAT October 2024). This approval adds to Zydus’ growing portfolio, with the company now holding 412 USFDA approvals and over 473 ANDA filings since 2003-04.

Zydus’ expertise in providing high-quality pharmaceutical products continues to meet global healthcare needs, expanding its footprint in the U.S. market while improving patient access to essential treatments.